Lancet study finds no significant clinical benefits of antiviral drug remdesivir

Although the study is the first randomised controlled trial -- considered the gold standard for evaluating the effectiveness of interventions -- of remdesivir, the researchers cautioned that interpretation of their findings is limited because the study was stopped early after they were unable to recruit enough patients due to the steep decline in cases in China.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2YfTJpL
via IFTTT